« Return to News | R&D Trends

Aesica, QRxPharma collaborate to promote Stealth Beadlets

Wednesday, July 24, 2013 09:30 AM

Aesica Pharmaceuticals, a global contract development and manufacturing organization (CDMO), has partnered with pharmaceutical company QRxPharma to globally promote QRxPharma’s proprietary Stealth Beadlets abuse deterrence technology.

Aesica will promote the Stealth Beadlets technology for use in controlled drugs formulations. It will enter into fee-for-service contracts with customers for development of the new Abuse Deterrent Formulations (ADF) of specific drugs, while QRxPharma will negotiate license terms.

Stealth Beadlets was developed for the MOXDUO controlled release formulation for the treatment of chronic pain. This program is ready for phase II studies and already has shown that Stealth Beadlets, incorporated into the company’s delayed release technology, provide a potential once-a-day to twice-a-day formulation. 

Stealth Beadlets can be incorporated into almost any potentially abused drug (e.g. opioids, amphetamines and sedatives) sold in solid dosage forms (e.g. tablet, capsule or sachet). It provides resistance against the extraction of active ingredients if crushed, solubilized or heated. Stealth Beadlets have no effect on the active ingredient release profile and consist entirely of patient-safe, low-cost excipients that have Generally Regarded As Safe (GRAS) status with the FDA.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.